Precision Neuroscience raises follow-on capital following FDA clearance and Medtronic partnership
Summary
Precision Neuroscience raised follow-on funding from existing investors including Founders Fund following the April 2025 FDA 510(k) clearance for Layer 7 and the January 2026 Medtronic partnership announcement. The company now has both regulatory clearance and the world's largest neurosurgical company as a commercial partner — a combination that dramatically de-risks the investment case and positions Precision for a substantial Series D financing in 2026.
Why it matters
Precision Neuroscience's dual milestone of FDA clearance plus Medtronic partnership in the same year represents an extraordinary commercial acceleration. The follow-on financing bridges to a Series D that should be substantially larger, reflecting the company's transformation from research-stage BCI startup to regulated commercial company with Big MedTech distribution.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial